SRN001 not checked

siRNAgen Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
2 in total

What this is

How it works
How it works isn't classified yet
How it’s given
“SRN001 is an investigational drug administered at doses of 45 mg, 90 mg, or 180 mg depending on cohort.”In the company’s words, NCT07407543 on ClinicalTrials.gov
Tested for
Idiopathic Pulmonary Fibrosis
Main trialPhase 1
“To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of SRN001 in healthy adult volunteers.”In the company’s words, NCT07407543 on ClinicalTrials.gov

Other drugs for Idiopathic Pulmonary Fibrosis

All 42 drugs for Idiopathic Pulmonary Fibrosis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 31 Oct 2026 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males
Phase 1Completed 15 Mar 2024 The First-in-human Study of SRN-001 in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow SRN001

Following is part of Solo: you see every change to SRN001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in